Cost-effectiveness of CBT, SSRI, and CBT+SSRI in the treatment for panic disorder

Acta Psychiatrica Scandinavica

Volumn 129, Issue 4, 2014, Pages 286-295

  Van Apeldoorn, F J ^a   Stant, A D ^a,b   Van Hout, W J P J ^b   Mersch, P P A ^b   Den Boer, J A ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Agoraphobia; Cognitive behavioral therapy; Cost effectiveness analysis; Drug treatment; Economic evaluation; Panic disorder; Randomized controlled trial

Indexed keywords

SEROTONIN UPTAKE INHIBITOR;

ADULT; AGORAPHOBIA; ARTICLE; COGNITIVE THERAPY; COST EFFECTIVENESS ANALYSIS; FEMALE; FOLLOW UP; HAMILTON ANXIETY SCALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; PANIC; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT; ADOLESCENT; CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; ECONOMICS; MULTIMODALITY CANCER THERAPY; PANIC DISORDER; PROCEDURES; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; COST-BENEFIT ANALYSIS; HUMANS; MALE; MIDDLE AGED; PANIC DISORDER; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84896053396     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/acps.12169     Document Type: Article

References (29)

1. Barrera TL, Norton PJ. Quality of life impairment in generalized anxiety disorder, social phobia, and panic disorder. J Anxiety Disord 2009;23:1086-1090.
2. Konnopka A, Leichsenring F, Leibing E, König HH. Cost-of-illness studies and cost-effectiveness analyses in anxiety disorders: a systematic review. J Affect Disord 2009;114:14-31.
3. Smit F, Willemse G, Meulenbeek P et al. Preventing panic disorder: cost-effectiveness analysis alongside a pragmatic randomised trial. Cost Eff Resour Alloc 2009;7:8 doi: 10.1186/1478-7547-7-8.
4. McHugh RK, Otto MW, Barlow DH, Gorman JM, Shear MK, Woods SW. Cost-efficacy of individual and combined treatments for panic disorder. J Clin Psychiatry 2007;68:1038-1044.
5. Hunsley J. Cost-effectiveness and medical cost-offset considerations in psychological service provisions. Can Psychol 2003;44:61-73.
6. Barlow DH, Gorman JM, Shear MK, Woods SW. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder. J Am Med Assoc 2000;283:2529-2536.
7. Smits JAJ, O'Cleirigh CM, Otto MW. Combining cognitive-behavioral therapy and pharmacotherapy for the treatment of panic disorder. J Cogn Ther 2006;20:75-84.
8. Simon NM, Safren SA, Otto MW, Sharma SG, Lanka GD, Pollack MH. Longitudinal outcome with pharmacotherapy in a naturalistic study of panic disorder. J Affect Disord 2002;69:201-208.
9. Mavissakalian RM, Perel JM. Duration of imipramine therapy and relapse in panic disorder with agoraphobia. J Clin Psychopharmacol 2002;22:294-299.
10. Otto MW, Deveney C. Cognitive-behavioral therapy and the treatment of panic disorder: efficacy and strategies. J Clin Psychiatry 2005;66(Suppl 4):28-32.
11. van Apeldoorn FJ, Timmerman ME, Mersch PPA et al. A randomized trial of Cognitive-Behavioral Therapy or Selective Serotonin Reuptake Inhibitor or both combined for panic disorder with or without agoraphobia: Treatment results through 1-year follow-up. J Clin Psychiatry 2010;71:574-586.
12. Clark DM. A cognitive approach to panic. Behav Res Ther 1986;24:461-470.
13. Craske MG, Barlow DH. Panic disorder and agoraphobia. In: Barlow DH, ed. Clinical handbook of psychological disorders. New York: Guilford, 1993: 1-47.
14. VanBalkom AJ, Van Dyck R, Van Megen HJGM et al. Richtlijn farmacotherapie angststoornissen. In: van Dyck R, van Megen HJGM, Timmerman L, van Vliet IM, Westenberg HGMVan Balkom AJ et al., eds. Richtlijn farmacotherapie angststoornissen. Amsterdam: Dries van Ingen, Uitgeverij Boom, 1998: 7-37.
15. van Apeldoorn FJ, Van Hout WJPJ, Mersch PPA et al. Is a Combined therapy more effective than either CBT or SSRI alone? Results of a multicenter trial on panic disorder with or without agoraphobia. Acta Psychiatr Scand 2008;117:260-270.
16. Koopmanschap MA, Rutten FF, Van Ineveld BM, Van Roijen L. The friction cost method for measuring indirect costs of disease. J Health Econ 1995;14:171-189.
17. Jacob-Tacken KH, Koopmanschap MA, Meerding WJ, Severens JL. Correcting for compensating mechanisms related to productivity costs in economic evaluations of health care programmes. Health Econ 2005;14:435-443.
18. Oostenbrink JB, Koopmanschap MA, Rutten F. Standardisation of costs: the Dutch manual for costing in economic evaluations. Pharmacoeconomics 2002;20:443-454.
19. Drummond MF, O'Brien BJ, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press, 1997.
20. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50-55.
21. Efron B, Tibshirani RJ. An introduction to the bootstrap. New York: Chapman & Hall, 1993.
22. Black WC. The CE plane: a graphic representation of cost-effectiveness. Med Decis Making 1990;10:212-214.
23. Fenwick E, O'Brien BJ, Briggs A. Cost-effectiveness acceptability curves - facts, fallacies and frequently asked questions. Health Econ 2004;13:405-415.
24. Briggs A, Clark T, Wolstenholme J, Clarke P. Missing...presumed at random: cost-analysis of incomplete data. Health Econ 2003;12:377-392.
25. Briggs AH, O'Brien BJ, Blackhouse G. Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies. Annu Rev Public Health 2002;23:377-401.
26. Johnston K, Gray A, Moher M, Yudkin P, Wright L, Mant D. Reporting the cost-effectiveness of interventions with nonsignificant effect differences: example from a trial of secondary prevention of coronary heart disease. Int J Technol Assess Health Care 2003;19:476-489.
27. Roy-Byrne PP, Sherbourne CD, Craske MG et al. Moving treatment research from clinical trials to the real world. Psychiatr Serv 2003;54:327-332.
28. Wells KB. Treatment research at the crossroads: the scientific interface of clinical trials and effectiveness research. Am J Psychiatry 1999;156:5-10.
29. Van Apeldoorna FJ, Van Houtb WJPJ, Timmermanb ME, Merschb PPA, den Boerba JA. Rate of improvement during and across three treatments for panic disorder with or without agoraphobia: Cognitive behavioral therapy, selective serotonin reuptake inhibitor or both combined. J Affect Disord 2013; 150:313-319.